Core Viewpoint - The report outlines the continuous supervision and compliance of Suzhou Nearshore Protein Technology Co., Ltd. after its IPO on the Sci-Tech Innovation Board, emphasizing the company's adherence to regulations and its operational performance despite financial losses. Continuous Supervision Work - The sponsor has established a robust continuous supervision system and work plan for the company, ensuring compliance with relevant regulations and effective communication [1][2] - The sponsor conducted regular visits, due diligence, and checks to monitor the company's operations and compliance with laws and regulations [1][2] - Throughout the supervision period, the company did not encounter any violations or breaches of commitments that required public disclosure [1][2] Financial Performance - For the first half of 2025, the company reported revenue of approximately 72.09 million, a year-on-year increase of 20.85% [8] - The net loss attributable to shareholders was approximately 24.22 million, with a net profit excluding non-recurring items of about -26.68 million [8] - The company’s cash flow from operating activities was -14.08 million, indicating a significant decline compared to the previous year [8] Core Competitiveness - The company has developed seven comprehensive technology platforms and 23 core technologies, which are crucial for maintaining its market competitiveness [5][9] - The company emphasizes the importance of protecting its core technologies to prevent leakage, which could adversely affect its operations [5][9] - A skilled and stable technical team is essential for sustaining technological leadership and core competitiveness [5][9] Industry Risks - The RNA vaccine and drug industry is still maturing, with uncertainties in demand for mRNA raw materials and reagents in various applications [7][8] - The company faces intense competition from both domestic and international players, which could impact its market position and profitability [6][7] Research and Development - The company invested approximately 26.1 million in R&D in the first half of 2025, accounting for 36.21% of its revenue, reflecting a slight decrease from the previous year [16] - As of June 30, 2025, the company holds 38 invention patents, 22 utility model patents, and 18 software copyrights, indicating a strong focus on innovation [16] Use of Raised Funds - The company raised approximately 186.30 million through its IPO, with 174.22 million remaining after deducting issuance costs, and has complied with regulations regarding the use of these funds [17][18]

Group 1 - The restructuring protein sector is leading the market with an increase of 3.07% [1] - Key companies in this sector include Kaiyin Technology, which rose by 8.7%, and Saiseng Pharmaceutical, which increased by 7.3% [1] - Other notable performers are Maiwei Biotechnology with a rise of 6.86%, and Baipusais, Hite Biotechnology, and Ruizhi Pharmaceutical, all of which saw gains exceeding 4% [1]

Market Performance - The three major A-share indices opened higher and maintained a fluctuating upward trend, reaching new highs for the year [1] - By the close, the Shanghai Composite Index, Shenzhen Component Index, and ChiNext Index rose by 0.5%, 0.53%, and 1.24% respectively, closing at 3665.92 points, 11351.63 points, and 2409.4 points [1] Sector Performance - The semiconductor sector showed strong performance, with Cambrian Technology hitting the daily limit and reaching a historical high [1] - Other sectors such as brain engineering, diversified finance, and electronic chemicals also saw significant gains, while aerospace, recombinant proteins, and minor metals experienced declines [1] Stock Performance - A total of 2084 stocks in A-shares rose, with 60 stocks hitting the daily limit, while 3167 stocks fell, including 5 stocks hitting the lower limit [1] Trading Volume - The trading volume in the Shanghai market was approximately 778.16 billion yuan, while the Shenzhen market's trading volume was about 1.103359 trillion yuan, leading to a combined trading volume of around 1.88 trillion yuan [1]

Market Performance - The three major A-share indices continued to rise, with the Shanghai Composite Index surpassing 3600 points again, closing at 3617 points, up 0.96% [1] - The Shenzhen Component Index increased by 0.59%, while the ChiNext Index rose by 0.39% [1] - Total trading volume reached 1.62 trillion yuan, an increase of 976 billion yuan compared to the previous trading day, with over 3900 stocks rising across the market [1] Sector Performance - PEEK materials saw significant gains, with stocks like Xinhan New Materials and Zhongxin Fluorine Materials hitting the daily limit [1] - The consumer electronics sector also performed well, with stocks such as Furi Electronics and Yidelong reaching the daily limit [1] - The communication equipment sector strengthened, with companies like Dongxin Peace and Changfei Optical Fiber hitting the daily limit [1] - The automotive parts sector was active, with stocks like Xinquan Co., Hunan Tianyan, and Zhongma Transmission also reaching the daily limit [1] - Other notable sectors with strong performance included copper cable high-speed connections, brain-computer interfaces, space station concepts, and plastic products [1] - Conversely, the traditional Chinese medicine sector declined, with Qizheng Tibetan Medicine hitting the daily limit down [1] - The Kimi concept saw a downturn, led by Wanxing Technology, while sectors like recombinant proteins, hepatitis concepts, and chemical pharmaceuticals also experienced significant declines [1] Index Summary - Shanghai Composite Index: 3617.60, +34.29 (+0.96%) [1] - Shenzhen Component Index: 11106.96, +65.40 (+0.59%) [1] - ChiNext Index: 2343.38, +9.05 (+0.39%) [1] - Other indices such as the Sci-Tech 50 and CSI 300 also showed positive movements [1]

Market Performance - The recombinant protein concept increased by 2.92%, ranking 7th among concept sectors, with 43 stocks rising, including Chengdu Xian Dao and Mai Wei Bio reaching a 20% limit up [1] - Leading gainers included Shen Zhou Cell, Hai Te Bio, and Ke Xing Pharmaceutical, with increases of 15.40%, 11.93%, and 10.14% respectively [1] - Decliners included ST Wei Ming, *ST Su Wu, and Lizu Group, with decreases of 5.01%, 4.81%, and 0.49% respectively [1] Capital Flow - The recombinant protein sector saw a net inflow of 188 million yuan, with 17 stocks receiving net inflows, and 5 stocks exceeding 30 million yuan in net inflow [1] - Shen Zhou Cell led with a net inflow of 217 million yuan, followed by Chengdu Xian Dao, Mai Wei Bio, and Hui Yu Pharmaceutical with net inflows of 126 million yuan, 96.87 million yuan, and 45.41 million yuan respectively [1] Capital Inflow Ratios - Leading stocks in capital inflow ratios included Shen Zhou Cell, Chengdu Xian Dao, and Cheng Da Bio, with net inflow ratios of 16.25%, 12.33%, and 10.79% respectively [2] - The top stocks in the recombinant protein concept based on capital flow included Shen Zhou Cell, Chengdu Xian Dao, and Mai Wei Bio, with respective daily turnover rates of 3.70%, 12.33%, and 17.80% [2]

Market Performance - The Shanghai Composite Index closed at 3473.13, with a slight increase of 0.02% [2] - The Shenzhen Component Index closed at 10435.51, down by 0.70% [2] - The CSI 300 Index closed at 3965.17, decreasing by 0.43% [2] - The ChiNext Index closed at 2130.19, down by 1.21% [2] - The STAR 50 Index closed at 978.29, with a decline of 0.66% [2] - The Beijing Stock Exchange 50 Index closed at 1401.92, down by 0.93% [2] Sector Performance - The top-performing sectors included Comprehensive (+2.57%), Utilities (+1.87%), Real Estate (+1.68%), Light Industry Manufacturing (+1.52%), and Environmental Protection (+1.10%) [3] - The worst-performing sectors were Coal (-2.04%), Pharmaceutical Biology (-0.97%), Communication (-0.77%), Home Appliances (-0.70%), and Electronics (-0.67%) [3] Concept Index Performance - The leading concept indices were Shipbuilding System (+5.23%), Biomass Power Generation (+2.83%), Virtual Power Plant (+2.62%), Cross-Border Payment (+2.36%), and Pumped Storage (+2.26%) [3] - The lagging concept indices included Recombinant Protein (-1.42%), Weight Loss Drugs (-1.10%), CRO Concept (-1.07%), AI PC (-1.02%), and AI Mobile Phones (-0.99%) [3] Market Outlook - The market experienced fluctuations with the Shanghai Composite Index managing to close slightly positive while the Shenzhen Component and ChiNext indices closed lower [5] - The report suggests that as the mid-year earnings forecasts and reports are released, the impact of earnings on individual stock performance will become significant [5] - Attention is expected to shift towards domestic policies, US-China tariffs, and potential interest rate cuts by the Federal Reserve, with the upcoming Political Bureau meeting being a key observation point [5] - Recommended sectors for attention include Non-ferrous Metals, Banking, Transportation, and Utilities [5]

Core Viewpoint - The A-share market showed a mixed performance with major indices experiencing slight increases, indicating a cautious market sentiment amid varied sector performances [1][2]. Market Performance - As of the midday close on July 3, the Shanghai Composite Index was at 3457.36 points, up 0.07%, the Shenzhen Component Index at 10490.5 points, up 0.75%, and the ChiNext Index at 2152.54 points, up 1.36% [1][2]. - The overall market breadth was relatively balanced, with the number of stocks rising and falling being approximately equal [2]. Sector Performance - The leading sectors included recombinant proteins, innovative drugs, and CRO (Contract Research Organization), while superconductors, BC batteries, and cultivated diamonds showed weakness [4]. Capital Flow - Main capital inflows were observed in the electronics, pharmaceutical biology, and communications sectors, while outflows were noted in non-ferrous metals, basic chemicals, and banking sectors [5]. - Specific stocks with significant net inflows included Industrial Fulian (14.98 billion), CATL (9.72 billion), and Luxshare Precision (7.82 billion) [5]. - Conversely, stocks facing notable net outflows included Yuyin Co. (5.52 billion), Northern Copper (5.16 billion), and Hunan Tianyan (3.38 billion) [5]. Institutional Insights - Guoyuan Securities highlighted the significance of including innovative drugs in commercial insurance directories, indicating a strengthening role of commercial insurance in the multi-tiered medical security system, which is expected to create more opportunities for the industry [7]. - CITIC Securities projected steady revenue growth in the computer industry by Q2 2025, with a focus on AI applications and computing power, suggesting investment in AI-related sectors such as management software, medical IT, and cloud services [7].

Market Overview - The Shanghai Composite Index has returned to 3400 points, with the ChiNext Index leading the gains [1][4] - The market showed a rebound with all three major indices closing in the green, and the ChiNext Index leading the rise [4][6] Market Performance - The closing points and percentage changes for major indices are as follows: - Shanghai Composite Index: 3402.32, up 0.52% [2] - Shenzhen Component Index: 10246.02, up 0.83% [2] - CSI 300: 3894.63, up 0.75% [2] - ChiNext Index: 2061.87, up 1.21% [2] - STAR 50: 980.93, down 0.20% [2] - Beijing Stock Exchange 50: 1427.91, unchanged [2] Sector Performance - The top-performing sectors include: - Non-ferrous metals: up 2.21% [3] - Agriculture, forestry, animal husbandry, and fishery: up 2.02% [3] - Non-bank financials: up 1.90% [3] - Automotive: up 1.70% [3] - Media: up 1.60% [3] - The underperforming sectors include: - Pharmaceutical and biological: down 0.41% [3] - Communication: down 0.28% [3] - Beauty and personal care: down 0.10% [3] - Public utilities: up 0.09% [3] - Food and beverage: up 0.21% [3] Concept Index Performance - The leading concept indices include: - Rare earth permanent magnet: up 4.90% [3] - E-sports: up 2.72% [3] - Cobalt: up 2.36% [3] - Integrated die-casting: up 2.26% [3] - Online gaming: up 2.22% [3] - The lagging concept indices include: - China-South Korea Free Trade Zone: down 1.35% [3] - CRO concept: down 0.90% [3] - Alzheimer's concept: down 0.90% [3] - Recombinant protein: down 0.82% [3] - Controlled nuclear fusion: down 0.80% [3] Future Outlook - The market is expected to maintain a slight positive growth in exports in June and July, despite a slowdown in growth and a widening decline in exports to the U.S. [6] - The report anticipates that the trade negotiations between China and the U.S. will ease trade tensions, supporting overseas demand [6] - The focus will be on the implementation of existing economic stabilization policies and potential new policies following the political bureau meeting in July [6] - Investment strategies should consider sectors such as technology growth, new consumption, high-end manufacturing, and high-dividend defensive assets [6]

Core Viewpoint - The article discusses the current state of the stock market, highlighting mixed performance across various indices and sectors, with a focus on the strength of certain stocks and sectors while others are experiencing declines [1][4]. Market Performance - As of June 10, the Shanghai Composite Index rose by 0.11% to 3403.52, while the Shenzhen Component Index fell by 0.23% to 10226.55, and the ChiNext Index decreased by 0.36% to 2053.94 [2][1]. - Overall, the market saw more declines than gains, with nearly 3400 stocks experiencing a drop [2]. Sector Performance - The pharmaceutical sector, particularly CRO (Contract Research Organization) stocks, showed strong performance, along with new consumption, solid-state batteries, and cross-border e-commerce concepts [4]. - Conversely, sectors such as computing, aerospace, AI applications, semiconductors, and new energy vehicles faced declines [4]. Capital Flow - Major inflows were observed in banking, pharmaceutical biology, electric equipment, public utilities, basic chemicals, non-ferrous metals, and light industry manufacturing sectors [5]. - Specific stocks like Industrial and Commercial Bank of China, Leshan Electric Power, and Bank of China saw net inflows of 742 million, 658 million, and 484 million respectively [6]. - On the other hand, stocks such as Huibo Yuntong, Inspur Information, and Tuo Wei Information faced significant net outflows of 323 million, 318 million, and 309 million respectively [7]. Asia-Pacific Market Overview - Major Asia-Pacific indices showed positive performance, with the Nikkei 225 rising by 1.01% to 38473.97, and the Korean Composite Index increasing by 0.75% to 2877.23 [9][10]. - The Australian S&P 200 Index also saw a rise of 0.79% to 8582.7 [10]. Market Sentiment and Strategy - Market volume remains insufficient, with a current level around 1.2 trillion, leading to a cautious outlook without significant policy breakthroughs [11]. - The strategy of focusing on individual stocks rather than indices is suggested, especially in sectors like smart manufacturing, military industry, and pharmaceuticals, which have shown recent performance but may not fully reflect long-term expectations [12].

Market Overview - The market trading volume remains at a medium-low level, with stock rotation occurring rapidly under the influence of existing funds [1] - Major indices showed slight declines this week, with the Shanghai Composite Index down 0.57%, Shenzhen Index down 0.46%, and the ChiNext Index down 1.47% [2] - The North Exchange 50 index experienced a significant drop of 3.68%, indicating a notable decline in micro-cap stocks [2] - The trading volume for micro-cap stocks approached the highest level since December 2023, indicating a crowded trading environment [2] Interest Rate Impact - On May 20, the central bank lowered the 1-year and 5-year Loan Prime Rates (LPR) by 10 basis points, resulting in rates of 3% and 3.5% respectively [3] - Major state-owned banks collectively reduced deposit rates, with 1-year fixed deposits falling below 1% and 5-year deposits below 1.5% [3] - The decline in risk-free rates is expected to increase the value of companies, particularly those with high dividend yields [3] Investment Opportunities - High-quality assets are defined by several criteria: high profitability/dividend certainty, industry leadership with high barriers to entry, low PE ratios (below 20 or even 10), and a revenue structure primarily focused on domestic markets [3] - The current market environment suggests a potential style shift from small-cap to large-cap stocks, benefiting high-quality assets [3][4] - Investors are advised to focus on certainty in uncertain markets, with a preference for companies that have stable operating performance and dividends [4]